Biopharma SHAKTI Scheme India
India is entering a decisive phase in the industrial growth story. With the announcement of the ₹10,000 crore Biopharma SHAKTI Programme, the Government of India has clearly indicated that there is a shift – from volume-led generic drug manufacturing to high value biologics, biosimilars and advanced therapeutic manufacture.
Unlike previous healthcare initiatives that were aimed almost wholly towards the access and affordability of medicines, Biopharma SHAKTI is quite fundamentally a manufacturing-led industrial policy. For entrepreneurs, MSME, manufacturing consultants and project investors, this initiative is a rare combination of policy support combined with import substitution demand as well as global export opportunity.
According to official updates released by the Press Information Bureau under the Ministry of Science & Technology, the programme is designed to develop national capabilities in biologics production, biosimilar production, clinical research infrastructure and advanced therapy production – a move which will put India firmly into global biopharma value chains.
Read More: Our Books
From Generic Dominance to Biopharma Sovereignty
India is known all over the world as the “pharmacy of the world” because of its leadership in the export of generic drugs. However, advanced biologics – such as monoclonal antibodies, recombinant proteins, insulin analogues and cell-based therapies – remain strongly import-dependent.
Why Biologics Are Different
Unlike small molecule generics, biologics require:
- Large-scale fermentation systems.
- Mammalian cell culture bioreactors
- Aseptic facilities that are cleanroom compliant
- Complicated downstream purification technologies
These high entry barriers have served to constrain domestic capacity in the past. The Biopharma SHAKTI Programme is a direct response to this gap and aims to develop policy supported demand visibility, research infrastructure and manufacturing incentives.
This strategy is very much a repeat of previous government-driven successes such as:
- Solar PV module manufacturing
- Mobile handset assembly
- Electronics and semiconductors clusters
Key Objectives of Biopharma SHAKTI Programmed
The programme is designed to provide long-term manufacturing competitiveness, and not short term subsidies. Its core objectives include:
- Developing domestic biologics manufacturing capacity
- Reducing import dependency on high value therapeutics
- Aiding indigenous biosimilar development
- Building clinical trial and translational research infrastructure
- Enabling the production of advanced therapies (cell and gene therapies)
For industrial investors this creates predictable institutional demand – an important consideration for capital-intensive manufacturing decisions.(Biopharma SHAKTI Scheme India)
Read More: Business Plans / Project Profiles
High Potential Manufacturing Opportunities for Enterprising People
1. Biosimilar Manufacturing Facilities
Biosimilars are the fastest-growing segment in the global pharmaceuticals. As patents expire on blockbuster biologics, demand for cost-effective biosimilars continues to increase.
Why biosimilar manufacturing is attractive:
- High entry barriers =competition is reduced
- Strong pricing power, relative to generics
- Long product life cycles
- Institutional and export-oriented demands
India has already had success stories. Biocon Ltd., which was founded by Kiran Mazumdar-Shaw, has jumped in early with biosimilars by investing on fermentation technology and insulin analogues- which enable entry into regulated global markets.
New entrants can replicate this success by focusing on niche biosimilars as opposed to mass portfolios.
2. Bioprocess Equipment Manufacturing (MSME Opportunity)
Major portion of bioprocess equipment of India is currently being imported, which include:
- Bioreactors and fermenters
- Chromatography skids
- Sterile filtration systems
- CIP/SIP automation modules
This creates an enormous opportunity for manufacturing driven by engineering MSMEs to manufacture:
- Stainless steel bioreactor vessels
- Process piping and aseptic tanks
- Utility automation systems
A classic example of vertical integration is that of Serum Institute of India, run by Adar Poonawalla, which has invested in fermentation infrastructure from early stages, instead of relying on imported equipment.
3. Enzyme and Cell Culture Media Manufacture
For first-generation entrepreneurs, upstream biopharma inputs provide a better entry point with fewer risks.
Manufacturing opportunities include:
- Amino acid nutrient blends
- Mammalian cell culture Growth Media
- Enzymes – recombinant and specialty enzymes
Advantages of this segment:
- Lower regulatory burden
- Shorter gestation periods
- Smaller cleanroom requirements
- High institutional demand reoccurs
These products are the backbone of any biologics manufacturing process.
Read More: Startup Selector
4. Contract Development & Manufacturing Organizations (CDMOs)
With more than 1,000 accredited clinical trial sites in the pipeline under the SHAKTI ecosystem, there should be a huge demand for outsourcing biomanufacturing.
CDMO facilities can cater to:
- Vaccine intermediates
- Therapeutic proteins
- Diagnostic biologics
Companies like Syngene International have shown just how scalable and lucrative this model can be if it is paired with global pharmaceutical clients.(Biopharma SHAKTI Scheme India)
Market Signals Favorable to Investment Decisions
|
Indicator |
Investor Insight |
|
Import Dependence |
High in advanced biologics |
|
Government Procurement |
Long-term institutional contracts |
|
Clinical Research |
1,000+ accredited sites planned |
|
Infrastructure |
Upgraded NIPER facilities |
|
Regulatory Alignment |
Faster CDSCO approvals |
In sum, these factors make it less risky for startups to plan capital intensive healthcare manufacturing.
Read More: Biopharma & AYUSH Manufacturing: New Business Opportunities After Budget 2026
Scalability and Profitability for Biopharma Manufacturing
From a techno-economic point of view, biopharma projects are very different from the classical pharma plants:
- More capital investment per facility
- Extended commissioning and validation times
- Strong pricing control after approval –
- Significantly higher export margins
Once approved, biologics have limited competition because of process complexity, which has made the IRRs superior compared to generic drug manufacturing.
Strategic Lessons from Industry Leaders
Successful Indian biopharma leaders have the following decision frameworks common:
- Entry into under-served technology segments
- Or “If you want to get somewhere” – “This is what you need to do”.
- Leveraging the regulation regulator quality barriers
- Long-term infrastructure mentality
These principles are still very relevant for new entrepreneurs considering SHAKTI aligned projects.
Importance of Detailed Feasibility Studies
Biopharma projects require strict pre-investment analysis including:
- Cleanroom and utility design
- Process flow and validation planning
- Raw material sourcing strategies
- Key issues will encompass the following:
At Niir Project Consultancy Services (NPCS), we specialize in preparation of Market Survey cum Detailed Techno-Economic Feasibility Reports (DPRs) on:
- Manufacturing processes
- Machinery and raw materials
- Capacity planning
- Project costing & financial modelling
- Profitability and Internal Rate of Return (IRR) analysis
Our goal is to assist investors in mitigating risk and maximizing scalability before capital deployment.
Read More: Top 15 Chemical Manufacturing Business Ideas in India with Huge Import Substitution Potential
Conclusion: A Decade-Defining Manufacturing Opportunity
The Biopharma SHAKTI Programme marks a turning point in India’s industrial strategy—moving decisively from generic dominance to advanced therapeutic manufacturing leadership.
For entrepreneurs aligned with policy-driven industrialization cycles, this initiative opens multiple entry points across the biopharma value chain. In capital-intensive sectors, government-backed ecosystem support often determines long-term viability.
This programme has the potential to define India’s healthcare manufacturing landscape for the next decade.(Biopharma SHAKTI Scheme India)
Commonly Asked Questions (FAQs)
Q1. Is biopharma manufacturing for MSMEs?
Yes. MSMEs may come in from bioprocess equipment, enzymes, culture media, and component manufacturing.
Q2. What are the Biggest Risks in Biopharma Projects?
Regulatory approvals, technology transfer costs, and long validation timelines.
Q3. How long is the gestation period?
Normally larger than traditional pharma plants because of complicated validation needs.
Q4. Can startups get in by contract manufacturing?
Yes. CDMO models provide revenue without having all the product development risk.
Q5. Why are biologics more profitable than generics?
Higher entry barriers and little competition gives better pricing control and margins.